RWD & Tempus Lens

Accelerate therapy development with real-world multimodal data

Advance discovery, innovation, and increase the likelihood of trial success with real-world clinical and molecular data, including DNA, RNA and whole slide pathology images.

Supporting Key Development Milestones

UPCOMING WEBINAR:
Discover novel biomarkers

Leverage real-world multimodal data and bioinformatics expertise to identify disease subtypes and power discovery approaches to lead to novel therapeutic opportunities
Read case study
UPCOMING WEBINAR:
Generate and validate hypotheses

Analyze your target of interest and identify the most appropriate patient population to evaluate for your therapy program
Read case study
UPCOMING WEBINAR:
Design late stage clinical trials

Design trials, validate biomarker strategies, define optimal populations to study and assess execution feasibility. Plus, conduct trial simulation and survival analysis to support trial success
Watch replay

Tempus lens

The full power of Tempus data at your fingertips

Harness the power of Tempus Lens, enhanced with Tempus One’s conversational AI capabilities, to analyze our extensive library of 8M+ de-identified research records. Uncover critical insights that can help accelerate innovation, and improve patient outcomes.

Explore now

How We Partner

Tempus offers flexible RWD solutions and services.

Data collaborations

Work with experienced Tempus scientists and biostatisticians to perform a scoped analysis based on your research objectives and criteria. Receive end-to-end support designing and executing retrospective data analyses.

Advanced analytics

Leverage Tempus Lens to conduct preliminary analyses and identify cohorts of interest, then migrate your records to Workspaces to generate additional insights in our cloud-based coding environment. Layer on AI agents for faster data curation and abstraction.

Top pharmaceutical and biotech companies trust Tempus to inform therapy development

WE’VE PARTNERED WITH

95%

of the top 20 pharma oncology companies
200+

biopharma companies

We are very pleased to collaborate with Tempus to enhance our data-driven R&D strategy and glean critical insights that will deepen our understanding of complex tumor biology, enhance access to predictive preclinical models, and increase the probability of clinical success across our diverse pipeline.

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca

Learn more about our partnership with AstraZeneca

We are looking forward to working together now and in the future, as we continue to progress our current clinical candidates, test rational combinations, and bring forward new ones, with the goal of getting medicines to patients as quickly as possible.

Jorge DiMartino, M.D., Ph.D., Chief Medical Officer and Executive Vice President, Clinical Development, Kronos Bio

Learn more about our partnership with Kronos Bio

Our collaboration with Tempus provided valuable insights to prioritize disease indications based on target expression and its relationship with clinical outcomes. The breadth of the Tempus database allowed us to correlate response of many standard therapeutic regimens to target expression to support our clinical trial plans.

Jonghwa Won, Executive Vice President, Head of Early Development, ABL Bio

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer, Genmab

The Tempus Difference

8M+

de-identified research records to power scientific discovery
2M+

records with imaging data
1.5M+

records with matched clinical data linked with genomic information
~300K+

records with whole transcriptomic profiles
60x larger

database than The Cancer Genome Atlas, the largest public genomic database

News & Insights

view all RESOURCES

UPCOMING WEBINAR:
In this Q&A, leaders from Tempus, Genialis, and UC San Diego discuss how transcriptomic data and AI are accelerating oncology R&D. Explore emerging applications, from AI-driven algorithms to platforms like Tempus Loop.
Read more
UPCOMING WEBINAR:
In this Q&A, Tempus leaders discuss how the Tempus platform leverages AI to support clinical research and patient care. Learn how they aggregate data and deliver insights to streamline trial matching and refine clinical strategy.
Read more
UPCOMING WEBINAR:
Leaders from Tempus and Erasca, Inc. discuss the transformative power of AI in oncology research and drug development. Watch their conversation from the AACR Annual Meeting 2025.
Watch now
UPCOMING WEBINAR:
Tempus launched its Fuses program to build a novel foundation model using its proprietary dataset. This initiative aims to transform therapeutic research and create the largest AI-enabled diagnostic platform to advance personalized care.
Read more
UPCOMING WEBINAR:
Tempus announced a multi-year collaboration with Boehringer Ingelheim to advance its cancer pipeline. Boehringer will leverage Tempus’ real-world data and AI platform to guide biomarker development and accelerate drug discovery.
Read more
UPCOMING WEBINAR:
Learn how Tempus’ AI solutions help researchers leverage multimodal data. In this webinar, leaders from healthcare and life sciences discuss the impact of these tools on accelerating research and discovery.
Watch replay

Trusted by hundreds of biopharma to power drug development

EXPLORE LIFE SCIENCES SOLUTIONS

The information on this page is intended for life sciences companies and focuses on research and development applications.

RWD & Tempus Lens

Supporting Key Development Milestones

Discover novel biomarkers

Generate and validate hypotheses

Design late stage clinical trials

Tempus lens

The full power of Tempus data at your fingertips

How We Partner

Data collaborations

Advanced analytics

Top pharmaceutical and biotech companies trust Tempus to inform therapy development

WE’VE PARTNERED WITH

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca

Jorge DiMartino, M.D., Ph.D., Chief Medical Officer and Executive Vice President, Clinical Development, Kronos Bio

Jonghwa Won, Executive Vice President, Head of Early Development, ABL Bio

Jan van de Winkel, Ph.D., Chief Executive Officer, Genmab

The Tempus Difference

News & Insights

In this Q&A, leaders from Tempus, Genialis, and UC San Diego discuss how transcriptomic data and AI are accelerating oncology R&D. Explore emerging applications, from AI-driven algorithms to platforms like Tempus Loop.

In this Q&A, Tempus leaders discuss how the Tempus platform leverages AI to support clinical research and patient care. Learn how they aggregate data and deliver insights to streamline trial matching and refine clinical strategy.

Leaders from Tempus and Erasca, Inc. discuss the transformative power of AI in oncology research and drug development. Watch their conversation from the AACR Annual Meeting 2025.

Tempus launched its Fuses program to build a novel foundation model using its proprietary dataset. This initiative aims to transform therapeutic research and create the largest AI-enabled diagnostic platform to advance personalized care.

Tempus announced a multi-year collaboration with Boehringer Ingelheim to advance its cancer pipeline. Boehringer will leverage Tempus’ real-world data and AI platform to guide biomarker development and accelerate drug discovery.

Learn how Tempus’ AI solutions help researchers leverage multimodal data. In this webinar, leaders from healthcare and life sciences discuss the impact of these tools on accelerating research and discovery.

Trusted by hundreds of biopharma to power drug development

See how one of the industry’s largest, structured real-world datasets can support you throughout the therapy development process.